Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Literature DB >> 26595810

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Deborah A Knight, Shin Foong Ngiow, Ming Li, Tiffany Parmenter, Stephen Mok, Ashley Cass, Nicole M Haynes, Kathryn Kinross, Hideo Yagita, Richard C Koya, Thomas G Graeber, Antoni Ribas, Grant A McArthur, Mark J Smyth.

Abstract

Entities: Disease Gene

Year: 2015 PMID： 26595810 PMCID： PMC4701538 DOI： 10.1172/JCI84828

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

Keyword Cloud
Cited

× No keyword cloud information.

7 in total

1. TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision.

Authors: Zeyu Chen; Zhicheng Ji; Shin Foong Ngiow; Sasikanth Manne; Zhangying Cai; Alexander C Huang; John Johnson; Ryan P Staupe; Bertram Bengsch; Caiyue Xu; Sixiang Yu; Makoto Kurachi; Ramin S Herati; Laura A Vella; Amy E Baxter; Jennifer E Wu; Omar Khan; Jean-Christophe Beltra; Josephine R Giles; Erietta Stelekati; Laura M McLane; Chi Wai Lau; Xiaolu Yang; Shelley L Berger; Golnaz Vahedi; Hongkai Ji; E John Wherry
Journal: Immunity Date: 2019-10-09 Impact factor: 31.745

Review 2. Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer.

Authors: Zhizhu Zhang; Ann Richmond; Chi Yan
Journal: Int J Mol Sci Date: 2022-07-01 Impact factor: 6.208

3. Co-Treatment of Chloroquine and Trametinib Inhibits Melanoma Cell Proliferation and Decreases Immune Cell Infiltration.

Authors: Simone Degan; Brian L May; Yingai J Jin; Manel Ben Hammoda; Huiying Sun; Guoqiang Zhang; Yan Wang; Detlev Erdmann; Warren Warren; Jennifer Y Zhang
Journal: Front Oncol Date: 2022-06-30 Impact factor: 5.738

7. Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma.

Authors: Rolando Pérez-Lorenzo; Stephanie O Erjavec; Angela M Christiano; Raphael Clynes
Journal: Oncotarget Date: 2021-01-19

7 in total

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

1. TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision.

Review 2. Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer.

3. Co-Treatment of Chloroquine and Trametinib Inhibits Melanoma Cell Proliferation and Decreases Immune Cell Infiltration.

Review 4. Immune system and melanoma biology: a balance between immunosurveillance and immune escape.

Review 5. Management of intracranial melanomas in the era of precision medicine.

Review 6. Combination immunotherapy: a road map.

7. Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma.